These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 870175)

  • 1. Relative biochemical aspects of low and high doses of methotrexate in mice.
    Zaharko DS; Fung WP; Yang KH
    Cancer Res; 1977 Jun; 37(6):1602-7. PubMed ID: 870175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion.
    Pinedo HM; Zaharko DS; Bull J; Chabner BA
    Cancer Res; 1977 Feb; 37(2):445-50. PubMed ID: 832268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues.
    Chabner BA; Young RC
    J Clin Invest; 1973 Aug; 52(8):1804-11. PubMed ID: 4719662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic alterations induced by 5-fluorouracil in bone marrow, intestinal mucosa, and tumor.
    Myers CE; Young RC; Chabner BA
    Cancer Res; 1976 May; 36(5):1653-8. PubMed ID: 1268826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokinetic comparison of thymidine and leucovorin rescue of marrow in humans after exposure to high-dose methotrexate.
    Howell SB; Krishan A; Frei E
    Cancer Res; 1979 Apr; 39(4):1315-20. PubMed ID: 311245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical and pharmacokinetic effects of leucovorin after high-dose methotrexate in a murine leukemia model.
    Sirotnak FM; Donsbach RC; Moccio DM; Dorick DM
    Cancer Res; 1976 Dec; 36(12):4679-86. PubMed ID: 1087182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic basis for differences in methotrexate sensitivity of normal proliferative tissues in the mouse.
    Sirotnak FM; Moccio DM
    Cancer Res; 1980 Apr; 40(4):1230-4. PubMed ID: 7357552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deoxyuridine suppression test: a comparison of two methods and effect of thymidine on the incorporation of 3H-deoxyuridine into DNA in human bone marrow cells.
    Taguchi H; Stafford DM; Chanarin I
    Acta Med Okayama; 1977 Apr; 31(2):113-20. PubMed ID: 143190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidine rescue of high-dose methotrexate in humans.
    Howell SB; Ensminger WD; Krishan A; Frei E
    Cancer Res; 1978 Feb; 38(2):325-30. PubMed ID: 637906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue pharmacokinetics, inhibition of DNA synthesis and tumor cell kill after high-dose methotrexate in murine tumor models.
    Sirotnak FM; Donsbach RC; Dorick DM; Moccio DM
    Cancer Res; 1976 Dec; 36(12):4672-8. PubMed ID: 1000510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation of tumor cells from patients with osteosarcoma and analysis of their sensitivity to methotrexate.
    Mordoh J; Chacón RD; Filmus J
    Cancer Res; 1981 Sep; 41(9 Pt 1):3621-8. PubMed ID: 6942915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved therapeutic index with high-dose methotrexate: comparison of thymidine-purine rescue with citrovorum factor rescue in mice.
    Samuels LL; Straw JA
    Cancer Res; 1984 Jun; 44(6):2278-84. PubMed ID: 6609764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Balb/c mice as a preclinical model for raltitrexed-induced gastrointestinal toxicity.
    Clarke SJ; Farrugia DC; Aherne GW; Pritchard DM; Benstead J; Jackman AL
    Clin Cancer Res; 2000 Jan; 6(1):285-96. PubMed ID: 10656460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevention of methotrexate toxicity by thymidine infusions in humans.
    Ensminger WD; Frei E
    Cancer Res; 1977 Jun; 37(6):1857-63. PubMed ID: 870189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential recovery of intestine, bone marrow, and thymus of rats with solid tumors following 5-fluorouracil administration.
    Hopkins HA; Kovacs CJ; Looney WB; Wakefield JA
    Cancer Biochem Biophys; 1976; 1(6):303-12. PubMed ID: 189899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporation of 5-fluorouracil into murine bone marrow DNA in vivo.
    Sawyer RC; Stolfi RL; Martin DS; Spiegelman S
    Cancer Res; 1984 May; 44(5):1847-51. PubMed ID: 6713387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity.
    Schuetz JD; Wallace HJ; Diasio RB
    Cancer Res; 1984 Apr; 44(4):1358-63. PubMed ID: 6704957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative toxicity of methotrexate in several tissues of mice bearing Lewis lung carcinoma.
    Zaharko DS; Dedrick RL; Peale AL; Drake JC; Lutz RJ
    J Pharmacol Exp Ther; 1974 Jun; 189(3):585-92. PubMed ID: 4843162
    [No Abstract]   [Full Text] [Related]  

  • 19. The mechanism of action of methotrexate in cultured L5178Y leukemia cells.
    Hryniuk WM
    Cancer Res; 1975 Apr; 35(4):1085-92. PubMed ID: 1054288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uptake of methotrexate, aminopterin, and methasquin and inhibition of dihydrofolate reductase and of DNA synthesis in mouse small intestine.
    Philips FS; Sirotnak FM; Sodergren JE; Hutchison DJ
    Cancer Res; 1973 Jan; 33(1):153-8. PubMed ID: 4682318
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.